Revimenib (revumenib)-REVUFORJ specifications price and purchase channel reference

Revumenib-REVUFORJ is a targeted small molecule drug mainly used for the treatment of patients with specific types of acute myeloid leukemia (AML) and other related hematological tumors. By inhibiting key molecular targets, Revimenib can block the proliferation signals of tumor cells, thereby clinically improving patient survival and disease control. This drug has not yet been approved for marketing in China, so patients need to obtain it through overseas channels.

In terms of specifications and prices, the common specifications of the original version of Revimanime are 110mg30 tablets and 160mg30 tablets. Each box sells for about 200,000 yuan, which is very expensive. This requires domestic patients to fully consider the economic costs when purchasing through overseas channels. Since the drug is a prescription drug, a doctor must issue a prescription before purchasing, and confirm that the patient meets the indications and medication safety requirements.

In addition to the U.S. version of the original drug, there are already generic drugs for sale in overseas markets, and their drug ingredients are basically the same as the original drug. The Laotian Lucius version of 110mg30 tablets is priced at approximately 6200 RMB per box, while the 160mg30 tablets are priced at approximately 8300RMB per box, which is significantly lower than the price of the original drug. Generic drugs provide a viable alternative for some patients, but they still need to be purchased through formal channels to ensure drug quality and efficacy.

In terms of drug purchase channels, domestic patients can obtain Revimenib through legal overseas pharmacies, cross-border medical service platforms or participation in clinical trials. During purchase and use, you should follow the doctor's guidance, complete the medication according to the prescribed dosage and course of treatment, and regularly monitor blood indicators and liver and kidney functions to ensure the safety and efficacy of treatment. Choosing formal channels and scientific management are the keys to ensuring medication safety.

Keyword tags: revimenib, acute myeloid leukemia, targeted therapy, price, generic drugs

Reference materials:https://www.accessdata.fda.gov/drugsatfda_docs/label/2024/215891s000lbl.pdf